Condition

Lymphoma, Large B-Cell, Diffuse

ClinicalTrials.gov condition label

Clinical trials7

Recruiting0

Common interventions14

Lead sponsors shown7

Clinical trials

7 shown

Observational Study of People Living With HIV Treated With CD19-directed CAR T CellNCT05784415 · 2021-05-22

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With AnthracyclinesNCT05728632 · 2019-01-01

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaNCT02743546 · 2016-07-20

Safety Study of SEA-CD40 in Cancer PatientsNCT02376699 · 2015-02-28

A Study Of PF-05082566 As A Single Agent And In Combination With RituximabNCT01307267 · 2011-06-21

The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)NCT01266668 · 2010-02-01

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionNCT00006436 · 2001-01-29

Common interventions

DuvortuxizumabDRUG1 EPOCHDRUG1 FilgrastimBIOLOGICAL1 GemcitabineDRUG1 IbrutinibDRUG1 Intravenous (IV) SEA-CD40DRUG1 Nab-paclitaxelDRUG1 NebivololDRUG1 PembrolizumabDRUG1 PF-05082566DRUG1 PlaceboDRUG1 RituximabBIOLOGICAL1 rituximabDRUG1 Subcutaneous (SC) SEA-CD40DRUG1

Leading sponsors

AIDS Malignancy Consortium1 Chonbuk National University Hospital1 Giulio Stefanini1 Janssen Research & Development, LLC1 National Cancer Institute (NCI)1 Pfizer1 Seagen Inc.1

Trial status mix

COMPLETED4

TERMINATED1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE13

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.